GA CoV-2 ELISA Kits

The CE-IVD GA-CoV-2 ELISA diagnostic workflow includes 3 screens for all immunodominant proteins of SARS-CoV-2 (N, S1, S2) achieving an overall specificity of 99%. The round of the screening includes the GA-CoV-2 IgM and GA-CoV-2 IgG with a sensitivity of 98% ten days post infection.

The GA CoV-2 IgG+ confirmatory test offers reliable support to differentiate other coronavirus infections and aids in the assessment of immune protection. Following a positive antibody result in screening, virus-specific antibodies against the N, S1 and S2 proteins are determined using this confirmatory test. It is known that antibodies to the nucleocapsid (N) protein, may have been generated during a previous SARS or MERS infection. By confirming double positivity, and the confirmation of S1 or S2 antibodies specifically, we increased the specificity in our clinical trial to 99%.

COVID-19 Diagnosis and Immune response

COVID-19 positive patients display a variety of symptoms with a large range of severity. Current research guidance suggests the length of time from initial infection with SARS-CoV-2 and appearance of first symptoms can be up to 14 days. RT-qPCR tests performed in hospital to confirm diagnosis in acute patients. This type of test examines the genetic material of the virus and give a positive result only if the virus is still present at a critical level. The tests are unable to identify individuals who have recovered.

The GA CoV-2 ELISA kits are serological tests that identify virus-specific antibodies in patients both during and post infection. Understanding the level of population exposure to SARS-CoV-2 and the number of recovered patients is key to a resilient pandemic response. Our simple GA CoV-2 Two Step ELISA confirms active cases and can indicate the level of immune protection following recovery by specifically identifying the IgG response to N-, S1- and S2- proteins are determined using GA CoV-2 IgG+ EIA  confirmatory test.
GA CoV-2 IgG/GA CoV-2 IgM

  • ELISA screening for the determination of IgG or IgM SARS CoV-2 antibodies in serum and plasma
  • 96 determinations per test kit including positive and negative controls
  • CE-IVD certified
  • 96 determinations per test kit including positive and negative controls
  • Fully automatable

GA CoV-2 IgG+

  • IgG confirmatory test specific for SARS CoV-2 N-, S1- and S2- proteins
  • 24×4 determinations per test kit including positive and negative controls
  • CE-IVD certified
  • Fully automatable

Ordering information